These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 26635183)

  • 1. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis.
    Harigai M; Ishiguro N; Inokuma S; Mimori T; Ryu J; Takei S; Takeuchi T; Tanaka Y; Takasaki Y; Yamanaka H; Watanabe M; Tamada H; Koike T
    Mod Rheumatol; 2016 Jul; 26(4):491-8. PubMed ID: 26635183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance.
    Harigai M; Ishiguro N; Inokuma S; Mimori T; Ryu J; Takei S; Takeuchi T; Tanaka Y; Takasaki Y; Yamanaka H; Yoshizawa Y; Chinen I; Nakao T; Koike T
    Mod Rheumatol; 2019 Sep; 29(5):747-755. PubMed ID: 30217117
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance.
    Harigai M; Tsuritani K; Yoshizawa Y; Atsumi T; Tanaka Y
    Mod Rheumatol; 2022 Apr; 32(3):508-516. PubMed ID: 34910191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan.
    Mimori T; Harigai M; Atsumi T; Fujii T; Kuwana M; Matsuno H; Momohara S; Takei S; Tamura N; Takasaki Y; Ikeuchi S; Kushimoto S; Koike T
    Mod Rheumatol; 2017 Sep; 27(5):755-765. PubMed ID: 27919207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.
    Koike T; Harigai M; Ishiguro N; Inokuma S; Takei S; Takeuchi T; Yamanaka H; Tanaka Y
    Mod Rheumatol; 2012 Aug; 22(4):498-508. PubMed ID: 21993918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks.
    Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Asai S; Yoshioka Y; Takemoto T; Terabe K; Asai N; Ishiguro N
    J Rheumatol; 2015 May; 42(5):786-93. PubMed ID: 25834204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders.
    Amano K; Matsubara T; Tanaka T; Inoue H; Iwahashi M; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T;
    Mod Rheumatol; 2015 Sep; 25(5):665-71. PubMed ID: 25698370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice.
    Mochizuki T; Yano K; Ikari K; Hiroshima R; Takaoka H; Kawakami K; Koenuma N; Shirahata T; Momohara S
    Mod Rheumatol; 2016 Jul; 26(4):499-506. PubMed ID: 26473281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-year safety and two-year effectiveness of etanercept in patients with rheumatoid arthritis in Japan: Results of long-term postmarketing surveillance.
    Yamanaka H; Hirose T; Endo Y; Sugiyama N; Fukuma Y; Morishima Y; Sugiyama N; Yoshii N; Miyasaka N; Koike T
    Mod Rheumatol; 2019 Sep; 29(5):737-746. PubMed ID: 30092161
    [No Abstract]   [Full Text] [Related]  

  • 10. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan.
    Koike T; Harigai M; Inokuma S; Inoue K; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Fujii K; Freundlich B; Suzukawa M
    J Rheumatol; 2009 May; 36(5):898-906. PubMed ID: 19332630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
    Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan.
    Tanaka Y; Mimori T; Yamanaka H; Nakajima R; Morita K; Kimura J; Takeuchi T
    Mod Rheumatol; 2019 Jul; 29(4):572-580. PubMed ID: 30009649
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.
    Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Takei S; Tanaka Y; Sano Y; Yaguramaki H; Yamanaka H
    J Rheumatol; 2014 Jan; 41(1):15-23. PubMed ID: 24187110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis.
    Takeuchi T; Tatsuki Y; Nogami Y; Ishiguro N; Tanaka Y; Yamanaka H; Kamatani N; Harigai M; Ryu J; Inoue K; Kondo H; Inokuma S; Ochi T; Koike T
    Ann Rheum Dis; 2008 Feb; 67(2):189-94. PubMed ID: 17644554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Up to 3-year results from a postmarketing surveillance study.
    Kameda H; Nishida K; Nanki T; Watanabe A; Oshima Y; Momohara S
    Mod Rheumatol; 2024 Oct; 34(6):1103-1114. PubMed ID: 38619380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.
    Lahaye C; Soubrier M; Mulliez A; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Mariette X; Gottenberg JE;
    Rheumatology (Oxford); 2016 May; 55(5):874-82. PubMed ID: 26822072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patients.
    Harigai M; Tsuchiya T; Kawana K; Kurimoto S
    Mod Rheumatol; 2018 Jan; 28(1):30-38. PubMed ID: 28388293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
    Rubbert-Roth A; Enejosa J; Pangan AL; Haraoui B; Rischmueller M; Khan N; Zhang Y; Martin N; Xavier RM
    N Engl J Med; 2020 Oct; 383(16):1511-1521. PubMed ID: 33053283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study.
    Sekiguchi M; Fujii T; Matsui K; Murakami K; Morita S; Ohmura K; Kawahito Y; Nishimoto N; Mimori T; Sano H;
    J Rheumatol; 2016 Nov; 43(11):1974-1983. PubMed ID: 27585689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry.
    Salmon JH; Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Meyer O; Solau-Gervais E; Marcelli C; Bardin T; Pane I; Baron G; Perrodeau E; Mariette X;
    Ann Rheum Dis; 2016 Jun; 75(6):1108-13. PubMed ID: 26048170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.